Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 14/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | NMT1 | P30419 | 1/20 | 0.36 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.35 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.35 |
| ▸ | NQO2 | P16083 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4324504 | 0.81 | MAP2K1 (0.44) | MAP2K1MAP2K2ABCB11NQO2MAPK1 | |
| SCHEMBL4333523 | 0.80 | MAP2K1 (0.34) | MAP2K1TP53MAPTMAP2K2ABCB11 | |
| SCHEMBL4327409 | 0.75 | MAP2K1 (0.50) | MAP2K1TP53MAPTNMT1MAP2K2 | |
| SCHEMBL4336107 | 0.73 | DGAT1 (0.37) | MAP2K1TP53MAPTMAP2K2MAPK1 | |
| SCHEMBL4337754 | 0.73 | L3MBTL1 (0.45) | MAP2K1TP53MAPTNMT1MAP2K2 | |
| SCHEMBL6205792 | 0.71 | MAP2K1 (0.43) | MAP2K1TP53MAPTMAP2K2DGAT1 | |
| SCHEMBL391367 | 0.71 | MAP2K1 (0.59) | MAP2K1MAP2K2ABCB11NQO2 | |
| SCHEMBL394009 | 0.70 | MAP2K1 (0.55) | MAP2K1MAP2K2 | |
| SCHEMBL3424014 | 0.69 | DGAT1 (0.34) | MAP2K1MAP2K2ABCB11NQO2DGAT1 | |
| SCHEMBL4321814 | 0.68 | MAP2K1 (0.49) | MAP2K1TP53MAPTMAP2K2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576072-B2 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576072-B2 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576072-B2 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-20050153942-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153942-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, MAPK9 | MAP2K1 77/4885TP53 213/4885MAPT 4825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.